Seaport Therapeutics (NASDAQ:SPTX) Director Purchases $99,300.00 in Stock

Seaport Therapeutics, Inc. (NASDAQ:SPTX) Director Denice Torres bought 5,000 shares of the business’s stock in a transaction on Tuesday, November 3rd. The shares were bought at an average cost of $19.86 per share, for a total transaction of $99,300.00. Following the completion of the acquisition, the director directly owned 5,000 shares in the company, valued at approximately $99,300. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Seaport Therapeutics Stock Performance

SPTX opened at $21.50 on Friday. The stock has a market capitalization of $1.15 billion and a P/E ratio of -1.77. The business has a 50 day simple moving average of $20.68. Seaport Therapeutics, Inc. has a 12-month low of $14.85 and a 12-month high of $28.38.

Seaport Therapeutics (NASDAQ:SPTX) last announced its quarterly earnings data on Monday, November 2nd. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.09. As a group, research analysts predict that Seaport Therapeutics, Inc. will post -4.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SPTX has been the subject of several recent analyst reports. Raymond James Financial began coverage on Seaport Therapeutics in a research note on Friday, September 25th. They issued a “strong-buy” rating and a $46.00 price target for the company. Seaport Research Partners set a $28.00 target price on shares of Seaport Therapeutics in a research report on Wednesday, October 14th. JonesTrading assumed coverage on shares of Seaport Therapeutics in a report on Wednesday, August 26th. They issued a “buy” rating and a $32.00 price target for the company. UBS Group reiterated a “buy” rating on shares of Seaport Therapeutics in a report on Thursday, October 8th. Finally, JPMorgan Chase & Co. raised their price objective on Seaport Therapeutics from $40.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.12.

Key Seaport Therapeutics News

Here are the key news stories impacting Seaport Therapeutics this week:

• Positive Sentiment: Director Denice Torres bought 5,000 shares for about $99,300 at an average price of $19.86, a notable insider purchase that may signal confidence in the company. Article: Seaport Therapeutics Director Purchases Shares
• Positive Sentiment: JPMorgan raised its price target to $41 from $40 and maintained an Overweight rating. HC Wainwright also reiterated its Buy rating and $50 target, reflecting continued analyst optimism, though targets are not guarantees. Seaport Therapeutics analyst information
• Neutral Sentiment: HC Wainwright made mixed earnings-estimate revisions: it narrowed its projected FY2026 loss to $3.95 per share from $4.09 and improved its Q4 2026 and Q1 2027 estimates, but its Q3 and Q4 2027 estimates imply somewhat larger losses. The revisions are modest and do not change its Buy rating or $50 target.
• Positive Sentiment: Seaport’s latest reported quarterly loss of $0.49 per share was better than the $0.58 loss analysts expected, providing a recent earnings beat that may help cushion concerns about future losses.

Hedge Funds Weigh In On Seaport Therapeutics

Several large investors have recently modified their holdings of SPTX. TRV GP VI LLC purchased a new position in Seaport Therapeutics during the 2nd quarter worth $44,769,742. Braidwell LP bought a new stake in shares of Seaport Therapeutics during the 2nd quarter worth approximately $10,860,000. Citadel Advisors LLC purchased a new position in shares of Seaport Therapeutics in the second quarter worth about $4,152,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Seaport Therapeutics during the 2nd quarter valued at about $1,793,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Seaport Therapeutics during the 2nd quarter worth about $1,629,000.

Seaport Therapeutics Company Profile

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for central nervous system (CNS) disorders. The company uses its Glyph platform, a technology designed to create prodrugs that may improve the delivery, tolerability, and effectiveness of certain therapies, including treatments intended to reach the brain.

Seaport’s pipeline includes investigational therapies for neurological and neuropsychiatric conditions. Its programs have included GTX-102, an oral investigational medicine being developed for Angelman syndrome, a rare genetic neurodevelopmental disorder, as well as additional candidates aimed at addressing unmet needs in CNS care.

The company was established with support from PureTech Health and is headquartered in Boston, Massachusetts.